Blood Pressure Effects on Cognition and Brain Blood Flow in Parkinson's Disease

This study is looking at how blood pressure affects thinking and blood flow in the brain for people with Parkinson's disease (PD). Specifically, it's interested in orthostatic hypotension (OH), which is low blood pressure when standing up. Researchers want to understand how low blood pressure might affect your thinking abilities, even if you don't feel dizzy. You might be able to join if you have early to moderate-stage Parkinson's disease, are at least 50 years old, and can walk without help. The study will use a tilt table (a special table that can move you from lying down to standing up) and cognitive tests to see how your thinking changes in different body positions. Success will be measured by changes in your verbal fluency test scores and brain blood flow over time, up to 30 months. The current status of this study is unclear, and it plans to enroll 60 participants.

Study design
This is an interventional study planning to enroll 60 participants. It will involve diagnostic tests using a tilt table.
What's involved
You will have a 3-hour screening visit for medical history, exams, and tests, including a tilt table test. If eligible, you'll have a separate 3-hour baseline study visit, where you'll need to abstain from caffeine for 24 hours.
Compensation
Not stated in the trial record.
Follow-up
Your verbal fluency and brain blood flow will be measured for up to 30 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05400174

Blood Pressure Effects on Cognition and Brain Blood Flow in PD

Recruiting
NAAges 50+InterventionalDiagnostic
University of California, San Diego
~60 participants
Updated 2026-08-07 on ClinicalTrials.gov
What's tested:Tilt table (upright position)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Delis-Kaplan Executive Function System Verbal Fluency Test score (number of words per minute). Minimum: 0; Maximum: N/A; higher is better
Measured over up to 30 months
+1 more outcome measured
Parkinson Disease
Orthostatic Hypotension
Dysautonomia

NCT05400174

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of California San Diego

    San Diego, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Please note that persons may not participate if they are taking any of the following:
medications to treat high blood pressure (called "antihypertensives") such as clonidine (Catapres), hydralazine, verapamil, diltiazem (Cartia), or medications ending in "-olol", "-artan", or "-pril")
diuretics (also called "water pills") such as furosemide (Lasix), bumetanide (Bumex), hydrochlorothiazide (HCTZ; Microzide), or spironolactone (Aldactone)
medications for enlarged prostate such as prazosin (Minipress), terazosin, doxazosin (Cardura), alfuzosin (Uroxatral), or tamsulosin (Flomax)
  • Delis-Kaplan Executive Function System Verbal Fluency Test score (number of words per minute). Minimum: 0; Maximum: N/A; higher is betterup to 30 months

    Participant says as many words in 1 minute as possible each of several letter or category prompts.

  • Oxygenated and deoxygenated hemoglobin change from baselineup to 30 months

    Functional near-infrared spectroscopy will measure relative changes in oxygenated and deoxygenated hemoglobin variables